{
    "ticker": "SIOX",
    "name": "Sio Gene Therapies Inc.",
    "description": "Sio Gene Therapies Inc. is a clinical-stage gene therapy company focused on developing transformative therapies for patients with severe neurological diseases. Founded in 2019 and headquartered in New York, Sio's proprietary gene therapy platform is designed to deliver innovative treatment solutions for conditions like metachromatic leukodystrophy (MLD) and other lysosomal storage disorders. The company is committed to addressing significant unmet medical needs and improving the lives of patients through cutting-edge gene therapies. Sio's lead product candidate, SGX301, is being developed for the treatment of MLD, with promising preclinical results paving the way for further clinical development. The company's mission is to leverage advanced gene therapy technologies to provide long-lasting and potentially curative treatments for devastating genetic diseases. Sio Gene Therapies is dedicated to establishing strategic partnerships and collaborations that enhance its research capabilities and accelerate the development of its therapeutic candidates, aiming to bring innovative solutions to the market in a timely manner.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2019",
    "website": "https://www.siogene.com",
    "ceo": "Garry Neil",
    "social_media": {
        "twitter": "https://twitter.com/SioGeneTherapy",
        "linkedin": "https://www.linkedin.com/company/sio-gene-therapies/"
    },
    "investor_relations": "https://ir.siogene.com",
    "key_executives": [
        {
            "name": "Garry Neil",
            "position": "CEO"
        },
        {
            "name": "David G. Moller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "SGX301"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sio Gene Therapies Inc. | Innovative Gene Therapy Solutions",
        "meta_description": "Learn about Sio Gene Therapies Inc., a leader in gene therapy focused on severe neurological diseases. Discover our innovative treatments and research advancements.",
        "keywords": [
            "Sio Gene Therapies",
            "Gene Therapy",
            "Neurological Diseases",
            "MLD Treatment",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Sio Gene Therapies known for?",
            "answer": "Sio Gene Therapies is known for developing innovative gene therapies for severe neurological diseases."
        },
        {
            "question": "Who is the CEO of Sio Gene Therapies?",
            "answer": "Garry Neil is the CEO of Sio Gene Therapies Inc."
        },
        {
            "question": "Where is Sio Gene Therapies headquartered?",
            "answer": "Sio Gene Therapies is headquartered in New York, New York, USA."
        },
        {
            "question": "What are Sio's main products?",
            "answer": "Sio's main product candidate is SGX301, focused on treating metachromatic leukodystrophy (MLD)."
        },
        {
            "question": "When was Sio Gene Therapies founded?",
            "answer": "Sio Gene Therapies was founded in 2019."
        }
    ],
    "competitors": [
        "AVTX",
        "PFE",
        "NVS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}